OPTIMA-AF Trial – One-month Dual Therapy After PCI Non-inferior to 12 Months, With Lower Bleeding in AF Patients
Key Points: • In patients with atrial fibrillation (AF) undergoing PCI, prolonged…
OCEAN: Ongoing Anticoagulation May Not be Necessary After 1-year Post Successful AF Ablation
Key Points: Atrial fibrillation (AF) increases the risk of stroke, and long-term…
CLOSURE-AF: Left Atrial Appendage Closure Fails to Achieve Noninferiority to Medical Therapy in AF Patients With High Bleeding Risk
Key Points: The CLOSURE AF study compared catheter-based left atrial appendage closure…
DARE-AF Trial: Dapagliflozin Did Not Reduce AF Burden After Catheter Ablation
Key Points: SGLT2 inhibitors have shown potential antiarrhythmic benefits in cardiometabolic disease,…
META-AF Trial – Metformin Reduces Arrhythmia Recurrence After AF Ablation in Overweight, Non-diabetic Patients
Key Points: Obesity is a well-established risk factor for atrial fibrillation (AF)…
VESALIUS-CV: PCSK9-Inhibitor Evolocumab Reduces MACE for Primary Prevention
Key Points: PCSK9-inhibitors – including evolocumab – are highly effective LDL-C–lowering medications…
DR10624, a First-in-Class FGF21/GLUCAGON/GLP-1 Receptor Triple Agonist, Significantly REDUCED Triglycerides, Lipids, and Liver Fat in Patients with Severe HYPERTRIGLYCERIDEMIA
Key Points: DR10624 is a first-in-class triple agonist of the FGF21, glucagon,…
NEWTON-CABG: Evolocumab Did Not Improve Vein Graft Patency After CABG
Key Points: Saphenous vein graft (SVG) failure is common after coronary artery…
In-Hospital Dapagliflozin Does Not Reduce CV Death or Worsening HF in Two Months, but Meta-Analysis Signals Potential Early Benefit
Key Points: Dapagliflozin is a key component of GDMT for heart failure,…
AI-Powered Virtual Assistant Boosts GDMT Optimization. ASSIST-HF SIRIO
Key Points: Optimization of GDMT is critical, particularly in the initial months…
Sacubitril/Valsartan Outperforms Enalapril in HFrEF due to Chronic Chagas Cardiomyopathy (CCC): The PARACHUTE-HF Trial
Key Points: Chronic Chagas cardiomyopathy (CCC) patients are underrepresented in heart failure…
An AI-enabled Stethoscope for Early Detection of Cardiac Conditions Increases Detection: TRICORDER
Key Points: Eighty percent of HF cases are diagnosed only during emergency…
Home-Based Hypertension Care Significantly Lowers Blood Pressure in Rural South Africa: The IMPACT-BP Trial
Key Points: Hypertension (HTN) is a major driver of stroke and cardiovascular…
Zilebesiran May Benefit Selected Groups of Uncontrolled Hypertension with High CV Risk: KARDIA-3
Key Points: Many patients do not achieve BP goals in hypertension (HTN)…
Essence-TIMI 73b: Olezarsen Safely and Effectively Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk
Key Points: Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to…
VICTOR: Vericiguat Did Not Meet Primary Endpoint But Reduced CV Death in Stable, Ambulatory HFrEF
Key Points: The VICOTRIA trial previously demonstrated that vericiguat reduced the risk…
VICTOR + VICTORIA: Vericiguat Showed Benefits Across the Spectrum of HFrEF Severity
Key Points: VICTORIA and VICTOR and were randomized trials that evaluated vericiguat…
ABC-AF Trial: Personalized Risk-Based Treatment Did Not Improve Outcomes in Patients with Atrial Fibrillation
Key Points: The ABC-AF trial evaluated whether treatment recommendations based on biomarker-based…
BaxHTN: Baxdrostat Significantly Reduced Blood Pressure in Patients with Uncontrolled or Resistant Hypertension
Key Points: Uncontrolled and resistant hypertension remains a major challenge despite treatment…
HI-PRO Trial: Extended Low-Intensity Apixaban Reduces Recurrent VTE in Patients with Provoked VTE and Enduring Risk Factors
Key Points: Standard anticoagulation for provoked venous thromboembolism (VTE) is often discontinued…